Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

NCT00138060 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: irinotecan
DRUG: 5 fluorouracil

Sponsor

Institut de Recherche Clinique sur les Cancers et le Sang

Collaborators

[object Object]